Boehringer Ingelheim Venture Fund has led a $30m series-B round for France-based Eyevensys, a clinical-stage biotechnology company developing non-viral gene therapies for retinal and other ophthalmic diseases.
Move comes as funds invested in DC have exceeded £1bn, but exposure to private markets assets was already available to DB members
GP bought the fasteners and fixings manufacturer as part of a succession process for the company
Existing investors Quilvest Capital Partners and Amin Khiari retain stakes in the group
GP intends to pursue an intense aggregation strategy with further acquisitions across the sector